Literature DB >> 12457803

Genetics of haemochromatosis.

Adrian Bomford1.   

Abstract

After identification of the hereditary haemochromatosis gene HFE, and receipt of confirmation that most patients with the condition were homozygous for a single, founder mutation (C282Y), most assumed that C282Y would be a prevalent, highly penetrant mutation in a gene that plays a key part in the regulation of iron absorption and of whole-body iron homoeostasis. With carrier rates of between 10% and 15%, and a homozygote frequency of about one-in-150 in people of northern European descent, C282Y is certainly prevalent. However, it is not highly penetrant. The pronounced variation in phenotype in individuals with the same gene mutation has prompted the search for modifier genes at other loci, and for environmental factors that might affect expression of the condition. Progress in our understanding of how HFE regulates the absorption of dietary iron has been slow, but much can be learnt from the study of the rare instances of haemochromatosis that involve mutations in newly-identified iron-metabolism genes, such as TFR2--a transferrin receptor isoform--and ferroportin1/Ireg1/mtp1--an intestinal iron transporter. The availability of definitive information on penetrance and the identity of genetic modifiers will aid the debate on whether population screening for haemochromatosis should be undertaken or whether alternative strategies should be implemented to improve early detection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12457803     DOI: 10.1016/S0140-6736(02)11607-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

Review 1.  Hepcidin: the missing link between hemochromatosis and infections.

Authors:  Houman Ashrafian
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  The Q283P amino-acid change in HFE leads to structural and functional consequences similar to those described for the mutated 282Y HFE protein.

Authors:  Chandran Ka; Gérald Le Gac; Francois-Yves Dupradeau; Jacques Rochette; Claude Férec
Journal:  Hum Genet       Date:  2005-06-18       Impact factor: 4.132

3.  Targeted screening for genetic haemochromatosis: a combined phenotype/genotype approach.

Authors:  M Bhavnani; D Lloyd; J Marples; K Pendry; M Worwood
Journal:  J Clin Pathol       Date:  2006-05       Impact factor: 3.411

4.  Normal iron metabolism and the pathophysiology of iron overload disorders.

Authors:  Chiang W Siah; John Ombiga; Leon A Adams; Debbie Trinder; John K Olynyk
Journal:  Clin Biochem Rev       Date:  2006-02

Review 5.  The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1).

Authors:  Andrew T McKie; David J Barlow
Journal:  Pflugers Arch       Date:  2003-06-27       Impact factor: 3.657

6.  Increased DMT1 but not IREG1 or HFE mRNA following iron depletion therapy in hereditary haemochromatosis.

Authors:  T Kelleher; E Ryan; S Barrett; M Sweeney; V Byrnes; C O'Keane; J Crowe
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

7.  HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.

Authors:  Domas Vaitiekus; Gintare Muckiene; Audrone Vaitiekiene; Liveta Sereikaite; Ruta Inciuraite; Ruta Insodaite; Daiva Cepuliene; Juozas Kupcinskas; Rasa Ugenskiene; Renaldas Jurkevicius; Elona Juozaityte
Journal:  Cardiovasc Toxicol       Date:  2020-08-03       Impact factor: 3.231

Review 8.  Screening for hemochromatosis: patients with liver disease, families, and populations.

Authors:  Sumedha P Galhenage; Charlie H Viiala; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2004-02

Review 9.  Where are all the iron men and women?

Authors:  Freiderich C Luft
Journal:  J Mol Med (Berl)       Date:  2003-12       Impact factor: 4.599

10.  HFE-Related Hemochromatosis: The Haptoglobin 2-2 Type Has a Significant but Limited Influence on Phenotypic Expression of the Predominant p.C282Y Homozygous Genotype.

Authors:  Gérald Le Gac; Chandran Ka; Isabelle Gourlaouen; Laurence Bryckaert; Anne-Yvonne Mercier; Brigitte Chanu; Virginie Scotet; Claude Férec
Journal:  Adv Hematol       Date:  2009-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.